The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 12, 2026
Snapshot (as of Oct 12, 2026): Novartis AG (NVS) pays a $4.67 annual dividend, yielding 3.30% at $143.75/share. Next ex-dividend date 2026-03-11. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 3.30%
Annual Dividend: $4.67 per share
Payout Ratio: 71.6%
Ex-Dividend Date: 2026-03-11
Dividend Frequency: annually
Sector: Healthcare
Years of Dividend History: 30
Novartis AG dividend investors are looking at a Swiss pharmaceutical company focused on prescription medicines across oncology, immunology, neuroscience, and cardiovascular diseases. NVS currently pays a 3.21% dividend yield. The trailing annual dividend rate is $4.4974 per share, paid annually, with the next ex-dividend date on March 11, 2026. A beta of 0.459 means NVS stock moves at less than half the volatility of the broader market, which suits income-focused investors who prioritize steadiness over price swings.
Novartis AG pays out 67.8% of earnings as dividends, a payout ratio classified as elevated (60–75%). That level is supported by a product portfolio anchored in prescription medicines, including therapies in oncology and cardiovascular diseases, where demand tends to be recurring by nature. Novartis AG dividend safety faces its main pressure point from that same payout ratio: at 67.8%, there is limited room to absorb an earnings decline before the dividend comes under strain. The history table also shows multiple years of year-over-year payment declines, which means the dividend has not been immune to fluctuation.
Over the past 14 years, Novartis AG dividend history shows a CAGR of 4.7% per year from 2011 to 2025. Per-share payments grew from $2.1084 to $3.9940 over that window (2026 data is partial and excluded from this calculation). The largest annual increase in the window was 24.9% in 2025, a sharp acceleration after several years of modest single-digit moves. The history also contains at least one year-over-year decline exceeding 5%, so growth has not been linear.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +6.3% | $3.33 (2022) | $3.99 (2025) |
| 5-Year | +5.3% | $3.09 (2020) | $3.99 (2025) |
| 10-Year | +4.7% | $2.52 (2015) | $3.99 (2025) |
NVS fits income-focused investors who want pharmaceutical sector exposure with a yield that runs above its own historical average. The current yield of 3.21% sits well above the 5-year average of 2.45%, which means today's entry point delivers more income than the stock has typically offered. The trade-off is a moderate (2–4%) yield paired with a 67.8% payout ratio that leaves less cushion than lower-payout peers. Growth has averaged 4.7% annually, which keeps pace with inflation in most environments but does not accelerate income meaningfully. What an investor gets here is a pharmaceutical business with low price volatility and a yield that is currently elevated relative to its own history. What they accept is a payout ratio that limits flexibility.
| Payment Date | Amount per Share |
|---|---|
| 2026-03-11 | $4.7402 |
| 2025-03-12 | $3.9940 |
| 2024-03-07 | $3.1986 |
| 2023-03-09 | $3.4987 |
| 2022-03-08 | $3.3253 |
| 2021-03-04 | $3.1991 |
| 2020-03-03 | $3.0874 |
| 2019-03-04 | $2.5672 |
| 2018-03-06 | $2.6676 |
| 2017-03-01 | $2.4606 |
| Year | Total Dividends |
|---|---|
| 2026 | $4.7402 |
| 2025 | $3.9940 |
| 2024 | $3.1986 |
| 2023 | $3.4987 |
| 2022 | $3.3253 |
Project income from NVS with the NVS dividend calculator or track your full portfolio with the dividend tracker.